Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties

Bone Marrow Transplantation volume 51, pages 418–423 (2016)Cite this article

Subjects

Abstract

Historically, invasive aspergillosis (IA) has been a major barrier for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The influence of invasive IA on long-term survival and on transplant-related complications has not been investigated in a larger patient cohort under current conditions. Our aim was to analyze the long-term outcome of patients undergoing allo-HSCT with a history of prior IA. We used European Society for Blood and Marrow Transplantation database data of first allo-HSCTs performed between 2005 and 2010 in patients with acute leukemia. One thousand one hundred and fifty patients with data on IA before allo-HSCT were included in the analysis. The median follow-up time was 52.1 months. We found no significant impact of IA on major transplant outcome variables such as overall survival, relapse-free survival, non-relapse mortality, cumulative incidence of acute GvHD grade II–IV, chronic GvHD, pulmonary complications and leukemia relapse. However, we found a trend toward lower overall survival (P=0.078, hazard ratio (HR) (95% confidence interval (CI)): 1.16 (0.98, 1.36)) and higher non-relapse mortality (P=0.150, HR (95% CI): 1.19 (0.94, 1.50)) in allo-HSCT recipients with pre-existing IA. Our data suggest that a history of IA should not generally be a contraindication when considering the performance of allo-HSCT in patients with acute leukemia.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494–503.

    PubMed  Google Scholar 

  2. Marr KA, Carter RA, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.

    Article  PubMed  Google Scholar 

  3. Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albos A . Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Haematologica 1997; 82: 297–304.

    CAS  PubMed  Google Scholar 

  4. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098–1103.

    Article  CAS  PubMed  Google Scholar 

  5. Martino R, Nomdedeu J, Altes A, Sureda A, Brunet S, Martinez C et al. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant 1994; 13: 265–269.

    CAS  PubMed  Google Scholar 

  6. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762–1768.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 2014; 20: 872–880.

    Article  PubMed  Google Scholar 

  8. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928–2936.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L et al. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia & lymphoma 2007; 48: 1799–1805.

    Article  Google Scholar 

  10. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH . Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61: 734–742.

    Article  CAS  PubMed  Google Scholar 

  11. Cordonnier C, Maury S, Pautas C, Bastie JN, Chehata S, Castaigne S et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943–948.

    Article  CAS  PubMed  Google Scholar 

  12. Reichenberger F, Habicht J, Kaim A, Dalquen P, Bernet F, Schlapfer R et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 1998; 158: 885–890.

    Article  CAS  PubMed  Google Scholar 

  13. Kruger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann Oncol 2005; 16: 1381–1390.

    Article  CAS  PubMed  Google Scholar 

  14. Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001, 392–421.

  15. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol 2013; 31: 2810–2818.

    Article  PubMed  Google Scholar 

  17. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40: 43–49.

    Article  PubMed  Google Scholar 

  18. Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)dagger. Ann Oncol 2015; 26: 21–33.

    Article  CAS  PubMed  Google Scholar 

  19. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416.

    Article  CAS  PubMed  Google Scholar 

  21. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347.

    Article  CAS  PubMed  Google Scholar 

  22. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129: 280–291; quiz 292-3.

    Article  PubMed  Google Scholar 

  23. Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 2011; 118: 1402–1412.

    Article  CAS  PubMed  Google Scholar 

  24. Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013; 122: 3359–3364.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Campus Virchow Klinikum, Allogeneic Stem Cell Transplantation Service, Berlin, Germany

    O Penack

  2. Department of Paediatric Hematology and Oncology, Policlinico GB Rossi, Verona, Italy

    G Tridello & S Cesaro

  3. EBMT Data Office, Leiden, The Netherlands

    J Hoek

  4. Service d'Hématologie Greffe, Hopital St Louis, Paris, France

    G Socié

  5. Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli Calmettes, Marseille, France

    D Blaise

  6. Department of Hematology, University Hospital, Basel, Switzerland

    J Passweg

  7. Department of Hematology, CHU Nantes, Nantes, France,

    P Chevallier

  8. BMT Unit, Queen Elizabeth Hospital, Birmingham, UK

    C Craddock

  9. Hématologie Clinique et thérapie cellulaire, CHU Bordeaux, Pessac, France

    N Milpied

  10. Department of Hematology, Leiden University Hospital, Leiden, The Netherlands,

    H Veelken

  11. Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

    J Maertens

  12. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

    P Ljungman

  13. Department of Hematology, Erasmus MC–Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands

    J Cornelissen

  14. Clinique d'hématologie, Hopital A Michallon, Grenoble, France

    A Thiebaut-Bertrand

  15. Department of Onco-Hematology, Nouvel Hopital Civil, Strasbourg, France

    B Lioure

  16. Department of Hematology, Centre Hospitalier Lyon Sud, Lyon, France,

    M Michallet

  17. Centro Interdipartimentale di Biostatistica e Bioinformatica, Università Tor Vergata, Rome, Italy

    S Iacobelli

  18. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel

    A Nagler

  19. Service d'Hématologie Clinique et de Thérapie Cellulaire, Hospital Saint Antoine, Paris, France

    M Mohty

Authors
  1. O Penack
    View author publications

    Search author on:PubMed Google Scholar

  2. G Tridello
    View author publications

    Search author on:PubMed Google Scholar

  3. J Hoek
    View author publications

    Search author on:PubMed Google Scholar

  4. G Socié
    View author publications

    Search author on:PubMed Google Scholar

  5. D Blaise
    View author publications

    Search author on:PubMed Google Scholar

  6. J Passweg
    View author publications

    Search author on:PubMed Google Scholar

  7. P Chevallier
    View author publications

    Search author on:PubMed Google Scholar

  8. C Craddock
    View author publications

    Search author on:PubMed Google Scholar

  9. N Milpied
    View author publications

    Search author on:PubMed Google Scholar

  10. H Veelken
    View author publications

    Search author on:PubMed Google Scholar

  11. J Maertens
    View author publications

    Search author on:PubMed Google Scholar

  12. P Ljungman
    View author publications

    Search author on:PubMed Google Scholar

  13. J Cornelissen
    View author publications

    Search author on:PubMed Google Scholar

  14. A Thiebaut-Bertrand
    View author publications

    Search author on:PubMed Google Scholar

  15. B Lioure
    View author publications

    Search author on:PubMed Google Scholar

  16. M Michallet
    View author publications

    Search author on:PubMed Google Scholar

  17. S Iacobelli
    View author publications

    Search author on:PubMed Google Scholar

  18. A Nagler
    View author publications

    Search author on:PubMed Google Scholar

  19. M Mohty
    View author publications

    Search author on:PubMed Google Scholar

  20. S Cesaro
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to O Penack.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Penack, O., Tridello, G., Hoek, J. et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. Bone Marrow Transplant 51, 418–423 (2016). https://doi.org/10.1038/bmt.2015.237

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2015.237

This article is cited by

Search

Advanced search

Quick links